Diane M. Citron
Michigan State University
Internal medicineSurgeryIn vitroCefoxitinMetronidazoleClindamycinBacteroidesErtapenemVancomycinStaphylococcus aureusBacteroides fragilisFusobacteriumAnaerobic bacteriaClostridium difficileAntibacterial agentAntimicrobialAntibioticsAnaerobic exerciseBacteriaMedicineBiologyMicrobiology
171Publications
58H-index
7,302Citations
Publications 171
Newest
#1Adam Cheknis (Edward Hines, Jr. VA Hospital)H-Index: 8
#2Dominique Devaris (MSD: Merck & Co.)
Last. Stuart Johnson (Loyola University Medical Center)H-Index: 59
view all 9 authors...
OBJECTIVES To investigate the molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile isolates from patients with C. difficile infection (CDI) from two Phase 3 clinical trials of surotomycin. METHODS In both trials [Protocol MK-4261-005 (NCT01597505) conducted across Europe, North America and Israel; and Protocol MK-4261-006 (NCT01598311) conducted across North America, Asia-Pacific and South America], patients with CDI were randomized (1:1) to receive oral surotomyci...
1 CitationsSource
#1Ellie J. C. Goldstein (UCLA: University of California, Los Angeles)H-Index: 66
#2C. Vreni MerriamH-Index: 26
Last. Diane M. CitronH-Index: 58
view all 3 authors...
Tedizolid's anaerobic activity is unappreciated; it was active against all 332 anaerobic isolates at ≤2 μg/ml except Bilophila wadsworthia, and was more active than linezolid against B. fragilis group sp. (MIC90 1 μg/ml vs 2-4 μg/ml). Tedizolid was active against Gram-positive anaerobes (MIC90: clostridia 0.25-1 μg/ml; anaerobic cocci ≤0.06 - 0.25 μg/ml). Coupled with clinical reports, clinicians should consider its use in mixed infections where S. aureus and anaerobes are involved.
2 CitationsSource
#2Diane M. CitronH-Index: 58
Last. Mary Beth Dorr (MSD: Merck & Co.)H-Index: 15
view all 8 authors...
From Monoclonal Antibodies for C. difficile Therapy II, no participants (n = 0/69) with a sustained clinical cure through 12 weeks following bezlotoxumab infusion experienced recurrent Clostridioides difficile infection (rCDI) after 9 months (versus actoxumab + bezlotoxumab, n = 2/65; versus placebo, n = 1/34). Bezlotoxumab's efficacy appears to be due to prevention rather than delayed onset of rCDI. CLINICAL TRIALS REGISTRATION: NCT01513239.
3 CitationsSource
BACKGROUND Bezlotoxumab reduced rates of recurrent Clostridioides difficile infection (rCDI) versus placebo in MODIFY I/II trial participants receiving antibacterial drug treatment for CDI. A secondary objective of MODIFY I/II was to assess bezlotoxumab's efficacy against C. difficile strains associated with increased rates of morbidity and mortality. METHODS In this post-hoc analysis of pooled MODIFY I/II data, efficacy endpoints were assessed in participants infected with restriction endonucle...
1 CitationsSource
#1Kerin TyrrellH-Index: 10
#2Diane M. CitronH-Index: 58
Last. Ellie J. C. GoldsteinH-Index: 66
view all 5 authors...
Abstract The in vitro activity of DS-2969b, a novel GyrB inhibitor, and six comparator agents was studied against 101 recent North American Clostridioides difficile isolates, 46 other intestinal anaerobes and 51 strains of methicillin-resistant Staphylococcus aureus. The MIC ranges (MIC90s) of DS-2969b against C. difficile and S. aureus were 0.03–0.125 (0.125) μg/ml and 0.125–1 (0.5) μg/ml, respectively. DS-2969b showed the greatest activity of the agents tested. There was no difference in MICs ...
5 CitationsSource
#1Richard VickersH-Index: 20
Last. Anne Kane (Tufts Medical Center)H-Index: 28
view all 6 authors...
Source
#1Ellie J. C. Goldstein (UCLA: University of California, Los Angeles)H-Index: 66
#2Diane M. CitronH-Index: 58
Last. Kerin L. TyrrellH-Index: 28
view all 3 authors...
Abstract Eravacycline, a novel fluorocycline antibiotic, has been evaluated against complicated mixed aerobic/anaerobic intra-abdominal infections but scant supporting in vitro data against anaerobes has been published. We found that eravacycline had good anaerobic in vitro activity with MICs of 4 μg/ml or less against all Bacteroides and Parabacteroides strains tested, except for two B. ovatus strains that had MICs of 8 μg/ml and one strain that had an MIC of 16 μg/ml. Eravacycline was four-to-...
17 CitationsSource
#1Ellie J. C. Goldstein (UCLA: University of California, Los Angeles)H-Index: 66
#2Diane M. CitronH-Index: 58
Last. Eliza S. LeoncioH-Index: 5
view all 4 authors...
Abstract Oral vancomycin is used to treat Clostridioides (Clostridium) difficile infection. Several different preparations are available including reconstituted IV solutions, vancomycin capsules, and grape flavored vancomycin oral solution kit (CutisPharma). The shelf life for IV after reconstitution varies between 7 and 14 days under refrigeration, and a standard 30 days for vancomycin oral solution kit (CutisPharma). The impact of storage on the in vitro potency was determined in 3 different v...
1 CitationsSource
#1Adam Cheknis (Edward Hines, Jr. VA Hospital)H-Index: 8
#2Stuart Johnson (LUC: Loyola University Chicago)H-Index: 59
Last. Dale N. Gerding (LUC: Loyola University Chicago)H-Index: 96
view all 11 authors...
The prevalence of C. difficile infection (CDI) and severe CDI are influenced by the prevalence of specific C. difficile strains, which are themselves influenced by antimicrobial susceptibility determinants as well as antimicrobial usage patterns. Restriction endonuclease analysis (REA) typing and antimicrobial susceptibility testing were used to characterize 1808 C. difficile isolates obtained from patients enrolled in four multicenter, multi-country, randomized CDI treatment trials conducted be...
17 CitationsSource
#1Ellie J. C. Goldstein (UCLA: University of California, Los Angeles)H-Index: 66
#2Diane M. CitronH-Index: 58
Last. C. Vreni MerriamH-Index: 26
view all 5 authors...
: Omadacycline was tested against 125 isolates recovered from infected cat and dog bites in humans. Its activity was similar to that of other compounds in the tetracycline class, and it was active against strains exhibiting tetracycline resistance. Against anaerobic isolates, resistance to tetracyclines was more prominent and omadacycline was the most active of the group. All isolates had omadacycline MICs of <1 μg/ml, with the exception of Eikenella corrodens, which showed reduced susceptibilit...
11 CitationsSource